Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of IQ-AI (LON: IQAI)are rallying on Friday after the company and its subsidiary, Imaging Biometrics, announced that its synthetic T1+C (Gad-Free) software application was awarded a patent by the US Patent and Trademark Office.
IQ-AI said the patent “underscores the potential of artificial intelligence (AI), its ability to streamline workflows, enhance diagnostic quality, and improve patient safety.”
The T1+C software application eliminates the need to intravenously inject contrast agent during medical imaging procedures. The fully automated AI platform accepts commonly acquired non-contrast medical images as inputs and outputs a synthetic contrast-enhanced image series that mimic actual, with contrast, images.
“This patented technology now available in the IQAI portfolio has the potential to directly impact routine clinical workflows globally,” said Trevor Brown, CEO of IQAI.
IQ-AI's share price is currently trading at 9.74p, up 23.68% after climbing to highs of 11.10p earlier in the session. In the past month, IQ-AI shares have gained 44.5%.
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .